A078160 Stock Overview
Engages in the cord blood bank business in South Korea and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
MEDIPOST Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩6,630.00 |
52 Week High | ₩15,700.00 |
52 Week Low | ₩6,590.00 |
Beta | 0.57 |
1 Month Change | -3.49% |
3 Month Change | -6.49% |
1 Year Change | -54.24% |
3 Year Change | -78.78% |
5 Year Change | -80.67% |
Change since IPO | -67.97% |
Recent News & Updates
Recent updates
Shareholder Returns
A078160 | KR Healthcare | KR Market | |
---|---|---|---|
7D | -0.3% | -4.1% | 1.1% |
1Y | -54.2% | -13.9% | 3.7% |
Return vs Industry: A078160 underperformed the KR Healthcare industry which returned -13.9% over the past year.
Return vs Market: A078160 underperformed the KR Market which returned 3.7% over the past year.
Price Volatility
A078160 volatility | |
---|---|
A078160 Average Weekly Movement | 3.8% |
Healthcare Industry Average Movement | 5.8% |
Market Average Movement | 5.0% |
10% most volatile stocks in KR Market | 11.2% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A078160 has not had significant price volatility in the past 3 months.
Volatility Over Time: A078160's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 298 | n/a | www.medi-post.co.kr |
MEDIPOST Co., Ltd. engages in the cord blood bank business in South Korea and internationally. The company operates through three divisions: Cord Blood Bank, Stem Cell Therapy, and Health Functional Food. It operates cord blood bank under the CELLTREE name.
MEDIPOST Co., Ltd. Fundamentals Summary
A078160 fundamental statistics | |
---|---|
Market cap | ₩226.07b |
Earnings (TTM) | ₩5.26b |
Revenue (TTM) | ₩69.14b |
42.9x
P/E Ratio3.3x
P/S RatioIs A078160 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A078160 income statement (TTM) | |
---|---|
Revenue | ₩69.14b |
Cost of Revenue | ₩27.95b |
Gross Profit | ₩41.19b |
Other Expenses | ₩35.93b |
Earnings | ₩5.26b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 154.40 |
Gross Margin | 59.57% |
Net Profit Margin | 7.61% |
Debt/Equity Ratio | 2.9% |
How did A078160 perform over the long term?
See historical performance and comparison